To include your compound in the COVID-19 Resource Center, submit it here.
Exelixis said Bristol-Myers will return all rights under a 2008 deal to XL281, effective Oct. 8. According to Exelixis,
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury